Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Revenue of Alpha Tau Medical Ltd. (DRTS)
Revenue in 2023 (TTM): $
According to Alpha Tau Medical Ltd.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Alpha Tau Medical Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-1,074,000 | $-34,606,000 | $-29,141,000 | $-29,157,000 |
| 2022 | $ | $-979,000 | $-32,742,000 | $-33,742,000 | $-33,762,000 |
| 2021 | $ | $-776,000 | $-13,215,000 | $-27,264,000 | $-27,271,000 |
| 2020 | $ | $-86,000 | $-9,158,000 | $-8,724,000 | $-8,882,000 |
| 2019 | $ | $ | $-7,944,000 | $-8,318,000 | $-8,464,000 |